Jump to content

Exosome (vesicle)

From Wikipedia, the free encyclopedia
(Redirected from Exovesicle)

Not to be confused with Exosome complex.
Exosome (extracellular vesicle)
Exosome cross-section showing hsp70 protein
Identifiers
MeSHD055354
Anatomical terminology

Exosomes, ranging in size from 30 to 150 nanometers,[1] are membrane-bound extracellular vesicles (EVs) that are produced in the endosomal compartment of most eukaryotic cells.[2][3][4] In multicellular organisms, exosomes and other EVs are found in biological fluids including saliva, blood, urine and cerebrospinal fluid.[5] EVs have specialized functions in physiological processes, from coagulation and waste management to intercellular communication.[6]

Exosomes are formed through the inward budding of a late endosome, also known as a multivesicular body (MVB).[7] The intraluminal vesicles (ILVs) of the multivesicular body (MVB) bud inward into the endosomal lumen. If the MVB fuses with the cell surface (the plasma membrane), these ILVs are released as exosomes.[8] Exosomes were also identified within the tissue matrix, coined Matrix-Bound Nanovesicles (MBV).[9] They are also released in vitro by cultured cells into their growth medium.[6][10][11] Enriched with a diverse array of biological elements from their source cells, exosomes contain proteins (such as adhesion molecules, cytoskeletons, cytokines, ribosomal proteins, growth factors, and metabolic enzymes), lipids (including cholesterol, lipid rafts, and ceramides), and nucleic acids (such as DNA, mRNA, and miRNA).[12] Since the size of exosomes is limited by that of the parent MVB, exosomes are generally thought to be smaller than most other EVs, from about 30 to 150 nanometres (nm) in diameter: around the same size as many lipoproteins but much smaller than cells.[13][6] Compared with EVs in general, it is unclear whether exosomes have unique characteristics or functions or can be separated or distinguished effectively from other EVs.[2]

EVs in circulation carry genetic material and proteins from their cell of origin, proteo-transcriptomic signatures that act as biomarkers.[7][5][6][14] In the case of cancer cells, exosomes may show differences in size, shape, morphology, and canonical markers from their donor cells. They may encapsulate relevant information that can be used for disease detection.[5][7] Consequently, there is a growing interest in clinical applications of EVs as biomarkers and therapies alike,[15] prompting establishment of an International Society for Extracellular Vesicles (ISEV) and a scientific journal devoted to EVs, the Journal of Extracellular Vesicles.

Background

[edit]

Exosomes were first discovered in the maturing mammalian reticulocyte (immature red blood cell) by Stahl and group in 1983 [16] and Johnstone and group in 1983[17] further termed 'exosomes' by Johnstone and group in 1987.[18] Exosomes were shown to participate in selective removal of many plasma membrane proteins[19] as the reticulocyte becomes a mature red blood cell (erythrocyte). In the reticulocyte, as in most mammalian cells, portions of the plasma membrane are regularly internalized as endosomes, with 50 to 180% of the plasma membrane being recycled every hour.[20] In turn, parts of the membranes of some endosomes are subsequently internalized as smaller vesicles. Such endosomes are called multivesicular bodies because of their appearance, with many small vesicles, (ILVs or "intralumenal endosomal vesicles"), inside the larger body. The ILVs become exosomes if the MVB merges with the cell membrane, releasing the internal vesicles into the extracellular space.[21]

Exosomes contain various molecular constituents of their cell of origin, including proteins and RNA. Although the exosomal protein composition varies with the cell and tissue of origin, most exosomes contain an evolutionarily-conserved common set of protein molecules. The protein content of a single exosome, given certain assumptions of protein size and configuration, and packing parameters, can be about 20,000 molecules.[22] The cargo of mRNA and miRNA in exosomes was first discovered at the University of Gothenburg in Sweden.[23]

The content of exosomes changes depending on the cells of origin, and they thereby reflect their originating cells. Analysis of the dynamic variation of exosomes may provide a valuable means of monitoring diseases.[24] In that study, the differences in cellular and exosomal mRNA and miRNA content was described, as well as the functionality of the exosomal mRNA cargo. Exosomes have also been shown to carry double-stranded DNA.[25]

Exosomes can transfer molecules from one cell to another via membrane vesicle trafficking, thereby influencing the immune system, such as dendritic cells and B cells, and may play a functional role in mediating adaptive immune responses to pathogens and tumors.[26][27] Therefore, scientists who are actively researching the role that exosomes may play in cell-to-cell signaling, often hypothesize that delivery of their cargo RNA molecules can explain biological effects. For example, mRNA in exosomes has been suggested to affect protein production in the recipient cell.[23][28][29] However, another study has suggested that miRNAs in exosomes secreted by mesenchymal stem cells (MSC) are predominantly pre- and not mature miRNAs.[30] Because the authors of this study did not find RNA-induced silencing complex-associated proteins in these exosomes, they suggested that only the pre-miRNAs, but not the mature miRNAs in MSC exosomes, have the potential to be biologically active in the recipient cells. Multiple mechanisms have been reported to be involved in loading miRNAs into exosomes, including specific motifs in the miRNA sequences, interactions with lncRNAs localized to the exosomes, interactions with RBPs, and post-translational modifications of Ago.[31]

Conversely, exosome production and content may be influenced by molecular signals received by the cell of origin. As evidence for this hypothesis, tumor cells exposed to hypoxia secrete exosomes with enhanced angiogenic and metastatic potential, suggesting that tumor cells adapt to a hypoxic microenvironment by secreting exosomes to stimulate angiogenesis or facilitate metastasis to more favorable environment.[32]

Terminology

[edit]

Evolving consensus in the field is that the term "exosome" should be applied strictly to an EV of endosomal origin. Since it can be difficult to prove such an origin after an EV has left the cell, variations on the term "extracellular vesicle" are often appropriate instead.[2][33]

Research

[edit]

Exosomes from red blood cells contain the transferrin receptor that is absent in mature erythrocytes. Dendritic cell-derived exosomes express MHC I, MHC II, and costimulatory molecules and have been proven to be able to induce and enhance antigen-specific T cell responses in vivo. In addition, the first exosome-based cancer vaccination platforms are being explored in early clinical trials.[34] Exosomes can also be released into urine by the kidneys, and their detection might serve as a diagnostic tool.[35][36][37] Urinary exosomes may be useful as treatment response markers in prostate cancer.[38][39] Exosomes secreted from tumour cells can deliver signals to surrounding cells and have been shown to regulate myofibroblast differentiation.[40] In melanoma, tumor-derived vesicles can enter lymphatics and interact with subcapsular sinus macrophages and B cells in lymph nodes.[41] A recent investigation showed that exosome release positively correlates with the invasiveness of ovarian cancer.[42] Exosomes released from tumors into the blood may also have diagnostic potential. Exosomes are remarkably stable in bodily fluids strengthening their utility as reservoirs for disease biomarkers.[43][44] Patient blood samples stored in biorepositories can be used for biomarker analysis as colorectal cancer cell-derived exosomes spiked into blood plasma could be recovered after 90 days of storage at various temperatures.[45]

In malignancies such as cancer, the regulatory circuit that guards exosome homeostasis is co-opted to promote cancer cell survival and metastasis.[46][29] In breast cancers, neratinib, a novel pan-ERBB inhibitor, is able to downmodulate the amount of HER2 released by exosomes, thus potentially reducing tumor dissemination.[47]

Urinary exosomes have also proven to be useful in the detection of many pathologies, such as genitourinary cancers and mineralocorticoid hypertension, through their protein and miRNA cargo."[48][15]

With neurodegenerative disorders, exosomes appear to play a role in the spread of alpha-synuclein, and are being actively investigated as a tool to both monitor disease progression as well as a potential vehicle for delivery of drug and stem cell based therapy.[49]

An online open access database containing genomic information for exosome content has been developed to catalyze research development within the field.[49]

Exosomes and intercellular communication

[edit]

Scientists are actively researching the role that exosomes may play in cell-to-cell signaling, hypothesizing that because exosomes can merge with and release their contents into cells that are distant from their cell of origin (see membrane vesicle trafficking), they may influence processes in the recipient cell.[50] For example, RNA that is shuttled from one cell to another, known as "exosomal shuttle RNA," could potentially affect protein production in the recipient cell.[28][23] The role played by exosomes in cell-cell or interorgan communication and metabolic regulation was reviewed by Samuelson and Vidal-Puig in 2018.[51] By transferring molecules from one cell to another, exosomes from certain cells of the immune system, such as dendritic cells and B cells, may play a functional role in mediating adaptive immune responses to pathogens and tumors.[26][41] Exosomal export of miRNA molecules is also linked to the arrest of inter cellular miRNA levels and affect their functionality by arresting them on heavy polysomes.[52]

Conversely, exosome production and content may be influenced by molecular signals received by the cell of origin. As evidence for this hypothesis, tumor cells exposed to hypoxia secrete exosomes with enhanced angiogenic and metastatic potential, suggesting that tumor cells adapt to a hypoxic microenvironment by secreting exosomes to stimulate angiogenesis or facilitate metastasis to more favorable environment.[32] It has recently been shown that exosomal protein content may change during the progression of chronic lymphocytic leukemia.[53]

A study hypothesized that intercellular communication of tumor exosomes could mediate further regions of metastasis for cancer. Hypothetically, exosomes can plant tumor information, such as tainted RNA, into new cells to prepare for cancer to travel to that organ for metastasis. The study found that tumor exosomal communication has the ability to mediate metastasis to different organs. Furthermore, even when tumor cells have a disadvantage for replicating, the information planted at these new regions, organs, can aid in the expansion of organ specific metastasis.[54]

Exosomes carry cargo, which can augment innate immune responses. For example, exosomes derived from Salmonella enterica-infected macrophages but not exosomes from uninfected cells stimulate naive macrophages and dendritic cells to secrete pro-inflammatory cytokines such as TNF-α, RANTES, IL-1ra, MIP-2, CXCL1, MCP-1, sICAM-1, GM-CSF, and G-CSF. Proinflammatory effects of exosomes are partially attributed to lipopolysaccharide, which is encapsulated within exosomes.[55]

Exosomes also mediate the cross talk between the embryo and maternal compartment during implantation.They help to exchange ubiquitous protein, glycoproteins, DNA and mRNA.[56]

Exosome biogenesis, secretion, and uptake

[edit]

Exosomes biogenesis

[edit]
Exosomes are extracellular vesicles having a unique biogenesis pathway via multivesicular bodies.

Exosome formation starts with the invagination of the multi-vesicular bodies (MVBs) or late endosomes to generate intraluminal vesicles (ILVs).[57] There are various proposed mechanisms for formation of MVBs, vesicle budding, and sorting. The most studied and well known is the endosomal sorting complex required for transport (ESCRT) dependent pathway. ESCRT machinery mediates the ubiquitinated pathway consisting of protein complexes; ESCRT-0, -I, -II, -III, and associated ATPase Vps4. ESCRT 0 recognizes and retains ubiquitinated proteins marked for packaging in the late endosomal membrane. ESCRT I/II recognizes the ESCRT 0 and starts creating involution of the membrane into the MVB. ESCRTIII forms a spiral-shaped structure constricting the neck. ATPase VPS4 protein drives the membrane scission.[58] Syndecan-syntenin-ALIX exosome biogenesis pathway are one of the ESCRT-independent or non-canonical pathways for exosome biogenesis.[59]

Exosome secretion

[edit]

The MVBs once formed are trafficked to the internal side of the plasma membrane. These MVBs are transported to the plasma membrane leading to fusion.[57] Many studies have shown that MVBs having higher cholesterol content fuse with the plasma membrane thus releasing exosomes.[60] The Rab proteins especially Rab 7 attached to the MVB recognizes its effector receptor. The SNARE complex (soluble N- ethylmaleimide- sensitive fusion attachment protein receptor) from the MVB and the plasma membrane interacts and mediates fusion.

Exosome uptake

[edit]

Specific targeting by exosomes is an active area of research. The exact mechanisms of exosome targeting is limited to a few general mechanisms like docking of the exosomes with specific proteins, sugars, and lipid, or micropinocytosis. The internalized exosomes are targeted to the endosomes which release their content in the recipient cell.[61][62]

Sorting and packaging of cargoes in exosomes

[edit]

Exosomes contain different cargoes; proteins, lipids, and nucleic acids. These cargoes are specifically sorted and packaged into exosomes. The contents packaged into exosomes are cell type specific and also influenced by cellular conditions.[57] Exosomal microRNAs (exomiRs) and proteins are sorted and packaged in exosomes. Villarroya-Beltri and colleagues identified a conserved GGAG specific motif, EXOmotif, in the miRNA packaged in the exosomes which was absent in the cytosolic miRNA (CLmiRNA), which binds to sumoylated heterogeneous nuclear riboprotein (hnRNP) A2B1 for exosome specific miRNA packaging[63] Proteins are packaged in ESCRT, tertraspanins, lipid- dependent mechanisms.[64] Exosomes are enriched in cholesterol, sphingomyelin, saturated phosphatidylcholine and phosphatidylethanolamine as compared to the plasma membrane of the cell.[64]

Isolation

[edit]

The isolation and detection of exosomes has proven to be complicated.[6][65] Due to the complexity of body fluids, physical separation of exosomes from cells and similar-sized particles is challenging. Isolation of exosomes using differential ultracentrifugation results in co-isolation of protein and other contaminants and incomplete separation of vesicles from lipoproteins.[66] Combining ultracentrifugation with micro-filtration or a gradient can improve purity.[67][68] Single step isolation of extracellular vesicles by size-exclusion chromatography has been demonstrated to provide greater efficiency for recovering intact vesicles over centrifugation,[69] although a size-based technique alone will not be able to distinguish exosomes from other vesicle types.[70] To isolate a pure population of exosomes a combination of techniques is necessary, based on both physical (e.g. size, density) and biochemical parameters (e.g. presence/absence of certain proteins involved in their biogenesis).[66][71] The use of reference materials such as trackable recombinant EV will assist in mitigating technical variation introduced during sample preparation and analysis.[72][73] Novel selective isolation methodology has been using a combination of immunoaffinity chromatography and asymmetric-flow field-flow fractionation to reduce the contamination from lipoproteins and other proteins when isolating from blood plasma.[74][75]

Exosomes are small extracellular vesicles that play a crucial role in cell-to-cell communication by transporting proteins, lipids, microRNAs, and functional mRNAs. Their potential in disease diagnostics, prognostics, and therapeutics has garnered significant interest in the biomedical field. Traditional methods for isolating exosomes are often hindered by low purity, inefficiency, lengthy processing times, and the need for substantial sample volumes and specialized equipment. Recent advancements in microfluidic devices, particularly those integrating nanostructures, offer promising alternatives for exosome isolation. These devices can be categorized based on their capture mechanisms: passive-structure-based affinity, immunomagnetic-based affinity, filtration, acoustofluidics, electrokinetics, and optofluidics. Microfluidic platforms not only improve the efficiency and purity of exosome isolation but also address the limitations of conventional methods, paving the way for their application in both research and clinical settings.[76]

Often, functional as well as antigenic assays are applied to derive useful information from multiple exosomes. Well-known examples of assays to detect proteins in total populations of exosomes are mass spectrometry and Western blot. However, a limitation of these methods is that contaminants may be present that affect the information obtained from such assays. Preferably, information is derived from single exosomes. Relevant properties of exosomes to detect include size, density, morphology, composition, and zeta potential.[77]

Detection

[edit]

Since the diameter of exosomes is typically below 100 nm and because they have a low refractive index, exosomes are below the detection range of many currently used techniques. A number of miniaturized systems, exploiting nanotechnology and microfluidics, have been developed to expedite exosome analyses. These new systems include a microNMR device,[78] a nanoplasmonic chip,[79] and a magneto-electrochemical sensor[80] for protein profiling; and an integrated fluidic cartridge for RNA detection.[81] Flow cytometry is an optical method to detect exosomes in suspension. Nevertheless, the applicability of flow cytometry to detect single exosomes is still inadequate due to limited sensitivity and potential measurement artifacts such as swarm detection.[82] Other methods to detect single exosomes are atomic force microscopy,[83] nanoparticle tracking analysis,[84] Raman microspectroscopy,[85] tunable resistive pulse sensing, and transmission electron microscopy.[82][47]

Bioinformatics analysis

[edit]

Exosomes contain RNA, proteins, lipids and metabolites that is reflective of the cell type of origin. As exosomes contain numerous proteins, RNA and lipids, large scale analysis including proteomics and transcriptomics is often performed. Currently, to analyse these data, non-commercial tools such as FunRich[86] can be used to identify over-represented groups of molecules. With the advent of Next generation sequencing technologies, the research on exosomes have been accelerated in not only cancer but various diseases. Recently, bioinformatics based analysis of RNA-Seq data of exosomes extracted from Trypanosoma cruzi has showed the association of these extracellular vesicles with various important gene products that strengthens the probability of finding biomarkers for Chagas disease.[87]

Therapeutics and carriers of drugs

[edit]

Researchers have also found that exosomes released from oral keratinocytes can accelerate wound healing, even when human exosomes were applied to rat wounds.[88]

Exosome-mediated delivery of superoxide dismutase extends life-span in Caenorhabditis elegans, apparently by reducing the level of reactive oxygen species.[89] Thus this system is being studied for its anti-aging potential.[89] This delivery system also improved survival under conditions of oxidative stress and heat.[89]

Exosomes are being actively researched for their potential in various therapeutic applications. For instance, dendritic cell (DC)-derived exosome vaccines, designed to present tumor antigens to the immune system, are undergoing clinical trials to evaluate their ability to generate personalized anti-tumor immune responses. These exosome-based vaccines have shown potential in generating strong cytotoxic T-lymphocyte responses in cancers like colorectal cancer and are being explored in trials for chronic diseases, such as diabetes and kidney disorders.[90]

Additionally, exosomes are promising carriers for chemotherapeutic agents like doxorubicin and paclitaxel.[91] These engineered exosomes can deliver drugs directly to tumors, thereby minimizing off-target effects while enhancing therapeutic efficacy . Exosomes' ability to cross biological barriers, such as the blood-brain barrier, makes them attractive for treating neurological diseases like glioblastoma and Alzheimer's disease. Preclinical studies suggest that exosomes loaded with amyloid-beta-clearing enzymes or antibodies can reduce amyloid-beta plaques, offering a potential treatment for Alzheimer's .

Moreover, exosomes derived from mesenchymal stem cells (MSCs) are being studied for their ability to promote tissue repair, particularly in cardiac repair post-myocardial infarction, where they deliver cardioprotective molecules that enhance recovery . Exosomes are also being investigated for their role in treating autoimmune conditions like multiple sclerosis and rheumatoid arthritis, where they can carry anti-inflammatory agents to regulate immune responses.[92] The versatility of exosomes continues to expand as they are also explored as vaccine platforms, particularly for infectious diseases such as COVID-19

Unapproved marketing

[edit]

Different forms of unproven exosomes are being marketed in the U.S. for a wide variety of health conditions by clinic firms, without authorization from the FDA. Often, these firms also sell non-FDA-approved stem cell injections as well. In late 2019, the FDA issued an advisory warning about noncompliant marketing of exosomes and injuries to patients in Nebraska related to injections of exosomes.[93] The agency also indicated that exosomes are officially drug products requiring pre-market approval. In 2020, the FDA cautioned several firms about marketing or use of exosomes for COVID-19 and other health conditions.[94][95][96]

Unapproved marketing of exosomes remains a persistent issue in the U.S., with some companies exploiting regulatory gaps and consumer confusion about these emerging therapies. These companies often operate in a grey zone, marketing exosome products as "minimally manipulated" and thereby attempting to avoid strict FDA regulations. In response, the FDA has increased its enforcement actions in recent years, emphasizing the need for exosome-based products to meet rigorous standards of safety and efficacy, similar to other biological drugs.

The FDA's warnings, particularly around exosome treatments for COVID-19, highlighted how some firms were capitalizing on the global pandemic to promote unverified therapies under the guise of immunity boosters or infection preventatives. Moreover, newer reports indicate that clinics continue to market exosomes for anti-aging, joint pain, and even neurological conditions like Alzheimer's, despite the lack of clinical evidence supporting these claims. Critics argue that this is a dangerous trend, with patients at risk of adverse effects such as inflammation, infection, and in some cases, serious injury.[97][98]

Interestingly, some clinics are now leveraging the loophole of "cosmetic" labeling to avoid scrutiny. They market exosomes in skincare products, claiming benefits like wrinkle reduction or skin rejuvenation. However, the FDA continues to assert that any use of exosomes, whether for cosmetic or therapeutic purposes, requires formal review and approval due to the potential biological effects of these extracellular vesicles. Regulatory experts warn that such practices, if unchecked, could undermine the credibility of legitimate exosome research and therapeutics being developed through proper channels.[99]

See also

[edit]

References

[edit]
  1. ^ Moghassemi S, Dadashzadeh A, Sousa MJ, Vlieghe H, Yang J, León-Félix CM, et al. (June 2024). "Extracellular vesicles in nanomedicine and regenerative medicine: A review over the last decade". Bioactive Materials. 36: 126–156. doi:10.1016/j.bioactmat.2024.02.021. PMC 10915394. PMID 38450204.
  2. ^ a b c Théry C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, et al. (2018). "Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines". Journal of Extracellular Vesicles. 7 (1): 1535750. doi:10.1080/20013078.2018.1535750. PMC 6322352. PMID 30637094.
  3. ^ Yáñez-Mó M, Siljander PR, Andreu Z, Zavec AB, Borràs FE, Buzas EI, et al. (2015). "Biological properties of extracellular vesicles and their physiological functions". Journal of Extracellular Vesicles. 4: 27066. doi:10.3402/jev.v4.27066. PMC 4433489. PMID 25979354.
  4. ^ van Niel G, D'Angelo G, Raposo G (April 2018). "Shedding light on the cell biology of extracellular vesicles". Nature Reviews. Molecular Cell Biology. 19 (4): 213–228. doi:10.1038/nrm.2017.125. PMID 29339798. S2CID 3944339.
  5. ^ a b c Nonaka T, Wong DT (June 2022). "Saliva Diagnostics". Annual Review of Analytical Chemistry. 15 (1): 107–121. Bibcode:2022ARAC...15..107N. doi:10.1146/annurev-anchem-061020-123959. PMC 9348814. PMID 35696523.
  6. ^ a b c d e van der Pol E, Böing AN, Harrison P, Sturk A, Nieuwland R (July 2012). "Classification, functions, and clinical relevance of extracellular vesicles". Pharmacological Reviews. 64 (3): 676–705. doi:10.1124/pr.112.005983. PMID 22722893. S2CID 7764903.
  7. ^ a b c Chen TY, Gonzalez-Kozlova E, Soleymani T, La Salvia S, Kyprianou N, Sahoo S, et al. (June 2022). "Extracellular vesicles carry distinct proteo-transcriptomic signatures that are different from their cancer cell of origin". iScience. 25 (6): 104414. Bibcode:2022iSci...25j4414C. doi:10.1016/j.isci.2022.104414. PMC 9157216. PMID 35663013.
  8. ^ Janas AM, Sapoń K, Janas T, Stowell MH, Janas T (June 2016). "Exosomes and other extracellular vesicles in neural cells and neurodegenerative diseases". Biochimica et Biophysica Acta (BBA) - Biomembranes. 1858 (6): 1139–1151. doi:10.1016/j.bbamem.2016.02.011. PMID 26874206.
  9. ^ Huleihel L, Hussey GS, Naranjo JD, Zhang L, Dziki JL, Turner NJ, et al. (June 2016). "Matrix-bound nanovesicles within ECM bioscaffolds". Science Advances. 2 (6): e1600502. Bibcode:2016SciA....2E0502H. doi:10.1126/sciadv.1600502. PMC 4928894. PMID 27386584.
  10. ^ Keller S, Sanderson MP, Stoeck A, Altevogt P (November 2006). "Exosomes: from biogenesis and secretion to biological function". Immunology Letters. 107 (2): 102–8. doi:10.1016/j.imlet.2006.09.005. PMID 17067686.
  11. ^ Spaull R, McPherson B, Gialeli A, Clayton A, Uney J, Heep A, et al. (April 2019). "Exosomes populate the cerebrospinal fluid of preterm infants with post-haemorrhagic hydrocephalus" (PDF). International Journal of Developmental Neuroscience. 73: 59–65. doi:10.1016/j.ijdevneu.2019.01.004. PMID 30639393. S2CID 58561998.
  12. ^ Moghassemi S, Dadashzadeh A, Sousa MJ, Vlieghe H, Yang J, León-Félix CM, et al. (June 2024). "Extracellular vesicles in nanomedicine and regenerative medicine: A review over the last decade". Bioactive Materials. 36: 126–156. doi:10.1016/j.bioactmat.2024.02.021. PMC 10915394. PMID 38450204.
  13. ^ Rudraprasad D, Rawat A, Joseph J (January 2022). "Exosomes, extracellular vesicles and the eye". Experimental Eye Research. 214: 108892. doi:10.1016/j.exer.2021.108892. PMID 34896308. S2CID 245028439.
  14. ^ Loewy MA (14 March 2023). "Saliva: The next frontier in cancer detection". Knowable Magazine. Annual Reviews. doi:10.1146/knowable-031323-1. S2CID 257541737.
  15. ^ a b Dhondt B, Van Deun J, Vermaerke S, de Marco A, Lumen N, De Wever O, et al. (June 2018). "Urinary extracellular vesicle biomarkers in urological cancers: From discovery towards clinical implementation". The International Journal of Biochemistry & Cell Biology. 99: 236–256. doi:10.1016/j.biocel.2018.04.009. PMID 29654900. S2CID 4876604.
  16. ^ Harding C, Stahl P (June 1983). "Transferrin recycling in reticulocytes: pH and iron are important determinants of ligand binding and processing". Biochemical and Biophysical Research Communications. 113 (2): 650–8. doi:10.1016/0006-291X(83)91776-X. PMID 6870878.
  17. ^ Pan BT, Johnstone RM (July 1983). "Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor". Cell. 33 (3): 967–78. doi:10.1016/0092-8674(83)90040-5. PMID 6307529. S2CID 33216388.
  18. ^ Johnstone RM, Adam M, Hammond JR, Orr L, Turbide C (July 1987). "Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes)". The Journal of Biological Chemistry. 262 (19): 9412–20. doi:10.1016/S0021-9258(18)48095-7. PMID 3597417.
  19. ^ van Niel G, Porto-Carreiro I, Simoes S, Raposo G (July 2006). "Exosomes: a common pathway for a specialized function". Journal of Biochemistry. 140 (1): 13–21. doi:10.1093/jb/mvj128. PMID 16877764. S2CID 43541754.
  20. ^ Huotari J, Helenius A (August 2011). "Endosome maturation". The EMBO Journal. 30 (17): 3481–500. doi:10.1038/emboj.2011.286. PMC 3181477. PMID 21878991.
  21. ^ Gruenberg J, van der Goot FG (July 2006). "Mechanisms of pathogen entry through the endosomal compartments". Nature Reviews. Molecular Cell Biology. 7 (7): 495–504. doi:10.1038/nrm1959. PMID 16773132. S2CID 429568.
  22. ^ Maguire G (January 2016). "Exosomes: smart nanospheres for drug delivery naturally produced by stem cells.". In Grumezescu AM (ed.). Fabrication and Self-Assembly of Nanobiomaterials. Vol. 1. William Andrew Publishing. pp. 179–209. doi:10.1016/B978-0-323-41533-0.00007-6. ISBN 978-0-323-41533-0.
  23. ^ a b c Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO (June 2007). "Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells". Nature Cell Biology. 9 (6): 654–9. doi:10.1038/ncb1596. PMID 17486113. S2CID 8599814.
  24. ^ Nuzhat Z, Kinhal V, Sharma S, Rice GE, Joshi V, Salomon C (March 2017). "Tumour-derived exosomes as a signature of pancreatic cancer - liquid biopsies as indicators of tumour progression". Oncotarget. 8 (10): 17279–17291. doi:10.18632/oncotarget.13973. PMC 5370040. PMID 27999198.
  25. ^ Thakur BK, Zhang H, Becker A, Matei I, Huang Y, Costa-Silva B, et al. (June 2014). "Double-stranded DNA in exosomes: a novel biomarker in cancer detection". Cell Research. 24 (6): 766–9. doi:10.1038/cr.2014.44. PMC 4042169. PMID 24710597.
  26. ^ a b Li XB, Zhang ZR, Schluesener HJ, Xu SQ (2006). "Role of exosomes in immune regulation". Journal of Cellular and Molecular Medicine. 10 (2): 364–75. doi:10.1111/j.1582-4934.2006.tb00405.x. PMC 3933127. PMID 16796805.
  27. ^ Hough KP, Chanda D, Duncan SR, Thannickal VJ, Deshane JS (April 2017). "Exosomes in immunoregulation of chronic lung diseases". Allergy. 72 (4): 534–544. doi:10.1111/all.13086. PMC 5462600. PMID 27859351.
  28. ^ a b Balaj L, Lessard R, Dai L, Cho YJ, Pomeroy SL, Breakefield XO, et al. (February 2011). "Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences". Nature Communications. 2 (2): 180. Bibcode:2011NatCo...2..180B. doi:10.1038/ncomms1180. PMC 3040683. PMID 21285958.
  29. ^ a b Oushy S, Hellwinkel JE, Wang M, Nguyen GJ, Gunaydin D, Harland TA, et al. (January 2018). "Glioblastoma multiforme-derived extracellular vesicles drive normal astrocytes towards a tumour-enhancing phenotype". Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 373 (1737): 20160477. doi:10.1098/rstb.2016.0477. PMC 5717433. PMID 29158308.
  30. ^ Chen TS, Lai RC, Lee MM, Choo AB, Lee CN, Lim SK (January 2010). "Mesenchymal stem cell secretes microparticles enriched in pre-microRNAs". Nucleic Acids Research. 38 (1): 215–24. doi:10.1093/nar/gkp857. PMC 2800221. PMID 19850715.
  31. ^ Gebert LF, MacRae IJ (January 2019). "Regulation of microRNA function in animals". Nature Reviews. Molecular Cell Biology. 20 (1): 21–37. doi:10.1038/s41580-018-0045-7. PMC 6546304. PMID 30108335.
  32. ^ a b Park JE, Tan HS, Datta A, Lai RC, Zhang H, Meng W, et al. (June 2010). "Hypoxic tumor cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes". Molecular & Cellular Proteomics. 9 (6): 1085–99. doi:10.1074/mcp.M900381-MCP200. PMC 2877972. PMID 20124223.
  33. ^ Witwer KW, Théry C (2019). "Extracellular vesicles or exosomes? On primacy, precision, and popularity influencing a choice of nomenclature". Journal of Extracellular Vesicles. 8 (1): 1648167. doi:10.1080/20013078.2019.1648167. PMC 6711079. PMID 31489144.
  34. ^ Mignot G, Roux S, Thery C, Ségura E, Zitvogel L (2006). "Prospects for exosomes in immunotherapy of cancer". Journal of Cellular and Molecular Medicine. 10 (2): 376–88. doi:10.1111/j.1582-4934.2006.tb00406.x. PMC 3933128. PMID 16796806.
  35. ^ Pisitkun T, Shen RF, Knepper MA (September 2004). "Identification and proteomic profiling of exosomes in human urine". Proceedings of the National Academy of Sciences of the United States of America. 101 (36): 13368–73. Bibcode:2004PNAS..10113368P. doi:10.1073/pnas.0403453101. PMC 516573. PMID 15326289.
  36. ^ "Urinary Exosome Protein Database". NHLBI. 2009-05-12. Retrieved 2009-10-01.
  37. ^ Nilsson J, Skog J, Nordstrand A, Baranov V, Mincheva-Nilsson L, Breakefield XO, et al. (May 2009). "Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer". British Journal of Cancer. 100 (10): 1603–7. doi:10.1038/sj.bjc.6605058. PMC 2696767. PMID 19401683.
  38. ^ "Fat capsules carry markers for deadly prostate cancer". The Medical News. 2009-05-13. Retrieved 2009-10-01.
  39. ^ Mitchell PJ, Welton J, Staffurth J, Court J, Mason MD, Tabi Z, et al. (January 2009). "Can urinary exosomes act as treatment response markers in prostate cancer?". Journal of Translational Medicine. 7 (1): 4. doi:10.1186/1479-5876-7-4. PMC 2631476. PMID 19138409.
  40. ^ Webber J, Steadman R, Mason MD, Tabi Z, Clayton A (December 2010). "Cancer exosomes trigger fibroblast to myofibroblast differentiation". Cancer Research. 70 (23): 9621–30. doi:10.1158/0008-5472.CAN-10-1722. PMID 21098712.
  41. ^ a b Pucci F, Garris C, Lai CP, Newton A, Pfirschke C, Engblom C, et al. (April 2016). "SCS macrophages suppress melanoma by restricting tumor-derived vesicle-B cell interactions". Science. 352 (6282): 242–6. Bibcode:2016Sci...352..242P. doi:10.1126/science.aaf1328. PMC 4960636. PMID 26989197.
  42. ^ Kobayashi M, Salomon C, Tapia J, Illanes SE, Mitchell MD, Rice GE (January 2014). "Ovarian cancer cell invasiveness is associated with discordant exosomal sequestration of Let-7 miRNA and miR-200". Journal of Translational Medicine. 12: 4. doi:10.1186/1479-5876-12-4. PMC 3896684. PMID 24393345.
  43. ^ Williams C, Royo F, Aizpurua-Olaizola O, Pazos R, Boons GJ, Reichardt NC, et al. (2018). "Glycosylation of extracellular vesicles: current knowledge, tools and clinical perspectives". Journal of Extracellular Vesicles. 7 (1): 1442985. doi:10.1080/20013078.2018.1442985. PMC 5844028. PMID 29535851.
  44. ^ Aizpurua-Olaizola O, Toraño JS, Falcon-Perez JM, Williams C, Reichardt N, Boons GJ (2018). "Mass spectrometry for glycan biomarker discovery". TrAC Trends in Analytical Chemistry. 100: 7–14. doi:10.1016/j.trac.2017.12.015. hdl:1874/364403.
  45. ^ Kalra H, Adda CG, Liem M, Ang CS, Mechler A, Simpson RJ, et al. (November 2013). "Comparative proteomics evaluation of plasma exosome isolation techniques and assessment of the stability of exosomes in normal human blood plasma". Proteomics. 13 (22): 3354–64. doi:10.1002/pmic.201300282. PMID 24115447. S2CID 45991971.
  46. ^ Syn N, Wang L, Sethi G, Thiery JP, Goh BC (July 2016). "Exosome-Mediated Metastasis: From Epithelial-Mesenchymal Transition to Escape from Immunosurveillance". Trends in Pharmacological Sciences. 37 (7): 606–617. doi:10.1016/j.tips.2016.04.006. PMID 27157716.
  47. ^ a b Santamaria S, Gagliani MC, Bellese G, Marconi S, Lechiara A, Dameri M, et al. (July 2021). "Imaging of Endocytic Trafficking and Extracellular Vesicles Released Under Neratinib Treatment in ERBB2+ Breast Cancer Cells". The Journal of Histochemistry and Cytochemistry. 69 (7): 461–473. doi:10.1369/00221554211026297. PMC 8246527. PMID 34126793.
  48. ^ Barros ER, Carvajal CA (2017-09-08). "Urinary Exosomes and Their Cargo: Potential Biomarkers for Mineralocorticoid Arterial Hypertension?". Frontiers in Endocrinology. 8: 230. doi:10.3389/fendo.2017.00230. PMC 5599782. PMID 28951728.
  49. ^ a b Tofaris GK (2017). "A Critical Assessment of Exosomes in the Pathogenesis and Stratification of Parkinson's Disease". Journal of Parkinson's Disease. 7 (4): 569–576. doi:10.3233/JPD-171176. PMC 5676982. PMID 28922170.
  50. ^ Dhondt B, Rousseau Q, De Wever O, Hendrix A (September 2016). "Function of extracellular vesicle-associated miRNAs in metastasis". Cell and Tissue Research. 365 (3): 621–41. doi:10.1007/s00441-016-2430-x. hdl:1854/LU-7250365. PMID 27289232. S2CID 2746182.
  51. ^ Samuelson I, Vidal-Puig AJ (May 2018). "Fed-EXosome: extracellular vesicles and cell-cell communication in metabolic regulation". Essays in Biochemistry. 62 (2): 165–175. doi:10.1042/EBC20170087. PMID 29717059.
  52. ^ Ghosh S, Bose M, Ray A, Bhattacharyya SN (March 2015). "Polysome arrest restricts miRNA turnover by preventing exosomal export of miRNA in growth-retarded mammalian cells". Molecular Biology of the Cell. 26 (6): 1072–83. doi:10.1091/mbc.E14-11-1521. PMC 4357507. PMID 25609084.
  53. ^ Prieto D, Sotelo N, Seija N, Sernbo S, Abreu C, Durán R, et al. (August 2017). "S100-A9 protein in exosomes from chronic lymphocytic leukemia cells promotes NF-κB activity during disease progression". Blood. 130 (6): 777–788. doi:10.1182/blood-2017-02-769851. hdl:20.500.12008/31377. PMID 28596424.
  54. ^ Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark M, et al. (November 2015). "Tumour exosome integrins determine organotropic metastasis". Nature. 527 (7578): 329–35. Bibcode:2015Natur.527..329H. doi:10.1038/nature15756. PMC 4788391. PMID 26524530.
  55. ^ Hui WW, Hercik K, Belsare S, Alugubelly N, Clapp B, Rinaldi C, et al. (February 2018). "Salmonella enterica Serovar Typhimurium Alters the Extracellular Proteome of Macrophages and Leads to the Production of Proinflammatory Exosomes". Infection and Immunity. 86 (2): e00386–17. doi:10.1128/IAI.00386-17. PMC 5778363. PMID 29158431.
  56. ^ Kurian NK, Modi D (February 2019). "Extracellular vesicle mediated embryo-endometrial cross talk during implantation and in pregnancy". Journal of Assisted Reproduction and Genetics. 36 (2): 189–198. doi:10.1007/s10815-018-1343-x. PMC 6420537. PMID 30362057.
  57. ^ a b c Hessvik NP, Llorente A (January 2018). "Current knowledge on exosome biogenesis and release". Cellular and Molecular Life Sciences. 75 (2): 193–208. doi:10.1007/s00018-017-2595-9. PMC 5756260. PMID 28733901.
  58. ^ Wollert T, Hurley JH (April 2010). "Molecular mechanism of multivesicular body biogenesis by ESCRT complexes". Nature. 464 (7290): 864–9. Bibcode:2010Natur.464..864W. doi:10.1038/nature08849. PMC 2851844. PMID 20305637.
  59. ^ Baietti MF, Zhang Z, Mortier E, Melchior A, Degeest G, Geeraerts A, et al. (June 2012). "Syndecan-syntenin-ALIX regulates the biogenesis of exosomes". Nature Cell Biology. 14 (7): 677–85. doi:10.1038/ncb2502. PMID 22660413. S2CID 30598897.
  60. ^ Möbius W, Ohno-Iwashita Y, van Donselaar EG, Oorschot VM, Shimada Y, Fujimoto T, et al. (January 2002). "Immunoelectron microscopic localization of cholesterol using biotinylated and non-cytolytic perfringolysin O". The Journal of Histochemistry and Cytochemistry. 50 (1): 43–55. doi:10.1177/002215540205000105. PMID 11748293.
  61. ^ Mathieu M, Martin-Jaular L, Lavieu G, Théry C (January 2019). "Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication". Nature Cell Biology. 21 (1): 9–17. doi:10.1038/s41556-018-0250-9. PMID 30602770. S2CID 57373483.
  62. ^ Shirazi S, Huang CC, Kang M, Lu Y, Ravindran S, Cooper LF (March 2021). "The importance of cellular and exosomal miRNAs in mesenchymal stem cell osteoblastic differentiation". Scientific Reports. 11 (1): 5953. Bibcode:2021NatSR..11.5953S. doi:10.1038/s41598-021-85306-2. PMC 7960990. PMID 33723364.
  63. ^ Villarroya-Beltri C, Gutiérrez-Vázquez C, Sánchez-Cabo F, Pérez-Hernández D, Vázquez J, Martin-Cofreces N, et al. (December 2013). "Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs". Nature Communications. 4 (1): 2980. Bibcode:2013NatCo...4.2980V. doi:10.1038/ncomms3980. PMC 3905700. PMID 24356509.
  64. ^ a b Villarroya-Beltri C, Baixauli F, Gutiérrez-Vázquez C, Sánchez-Madrid F, Mittelbrunn M (October 2014). "Sorting it out: regulation of exosome loading". Seminars in Cancer Biology. 28: 3–13. doi:10.1016/j.semcancer.2014.04.009. PMC 4640178. PMID 24769058.
  65. ^ Thind A, Wilson C (2016). "Exosomal miRNAs as cancer biomarkers and therapeutic targets". Journal of Extracellular Vesicles. 5: 31292. doi:10.3402/jev.v5.31292. PMC 4954869. PMID 27440105.
  66. ^ a b Liangsupree T, Multia E, Riekkola ML (January 2021). "Modern isolation and separation techniques for extracellular vesicles". Journal of Chromatography A. 1636: 461773. doi:10.1016/j.chroma.2020.461773. PMID 33316564.
  67. ^ Tauro BJ, Greening DW, Mathias RA, Ji H, Mathivanan S, Scott AM, et al. (February 2012). "Comparison of ultracentrifugation, density gradient separation, and immunoaffinity capture methods for isolating human colon cancer cell line LIM1863-derived exosomes". Methods. 56 (2): 293–304. doi:10.1016/j.ymeth.2012.01.002. PMID 22285593.
  68. ^ Van Deun J, Mestdagh P, Sormunen R, Cocquyt V, Vermaelen K, Vandesompele J, et al. (2014). "The impact of disparate isolation methods for extracellular vesicles on downstream RNA profiling". Journal of Extracellular Vesicles. 3: 24858. doi:10.3402/jev.v3.24858. PMC 4169610. PMID 25317274.
  69. ^ Böing AN, van der Pol E, Grootemaat AE, Coumans FA, Sturk A, Nieuwland R (2014). "Single-step isolation of extracellular vesicles by size-exclusion chromatography". Journal of Extracellular Vesicles. 3: 23430. doi:10.3402/jev.v3.23430. PMC 4159761. PMID 25279113.
  70. ^ Li X, Corbett AL, Taatizadeh E, Tasnim N, Little JP, Garnis C, et al. (March 2019). "Challenges and opportunities in exosome research-Perspectives from biology, engineering, and cancer therapy". APL Bioengineering. 3 (1): 011503. doi:10.1063/1.5087122. PMC 6481742. PMID 31069333.
  71. ^ Dhondt B, Lumen N, De Wever O, Hendrix A (September 2020). "Preparation of Multi-omics Grade Extracellular Vesicles by Density-Based Fractionation of Urine". STAR Protocols. 1 (2): 100073. doi:10.1016/j.xpro.2020.100073. PMC 7580105. PMID 33111109.
  72. ^ Dhondt B, Geeurickx E, Tulkens J, Van Deun J, Vergauwen G, Lippens L, et al. (11 March 2020). "Unravelling the proteomic landscape of extracellular vesicles in prostate cancer by density-based fractionation of urine". Journal of Extracellular Vesicles. 9 (1): 1736935. doi:10.1080/20013078.2020.1736935. PMC 7144211. PMID 32284825.
  73. ^ Geeurickx E, Tulkens J, Dhondt B, Van Deun J, Lippens L, Vergauwen G, et al. (July 2019). "The generation and use of recombinant extracellular vesicles as biological reference material". Nature Communications. 10 (1): 3288. Bibcode:2019NatCo..10.3288G. doi:10.1038/s41467-019-11182-0. PMC 6650486. PMID 31337761.
  74. ^ Multia E, Tear CJ, Palviainen M, Siljander P, Riekkola ML (December 2019). "Fast isolation of highly specific population of platelet-derived extracellular vesicles from blood plasma by affinity monolithic column, immobilized with anti-human CD61 antibody". Analytica Chimica Acta. 1091: 160–168. Bibcode:2019AcAC.1091..160M. doi:10.1016/j.aca.2019.09.022. hdl:10138/321264. PMID 31679569. S2CID 203147714.
  75. ^ Multia E, Liangsupree T, Jussila M, Ruiz-Jimenez J, Kemell M, Riekkola ML (October 2020). "Automated On-Line Isolation and Fractionation System for Nanosized Biomacromolecules from Human Plasma". Analytical Chemistry. 92 (19): 13058–13065. doi:10.1021/acs.analchem.0c01986. PMC 7586295. PMID 32893620.
  76. ^ Le MC, Fan HZ (2021-01-21). "Exosome isolation using nanostructures and microfluidic devices". Biomedical Materials. 16 (2): 022005. doi:10.1088/1748-605X/abde70. ISSN 1748-6041. PMC 8082697. PMID 33477118.
  77. ^ van der Pol E, Hoekstra AG, Sturk A, Otto C, van Leeuwen TG, Nieuwland R (December 2010). "Optical and non-optical methods for detection and characterization of microparticles and exosomes". Journal of Thrombosis and Haemostasis. 8 (12): 2596–607. doi:10.1111/j.1538-7836.2010.04074.x. PMID 20880256. S2CID 37878753.
  78. ^ Shao H, Chung J, Balaj L, Charest A, Bigner DD, Carter BS, et al. (December 2012). "Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy". Nature Medicine. 18 (12): 1835–40. doi:10.1038/nm.2994. PMC 3518564. PMID 23142818.
  79. ^ Im H, Shao H, Park YI, Peterson VM, Castro CM, Weissleder R, et al. (May 2014). "Label-free detection and molecular profiling of exosomes with a nano-plasmonic sensor". Nature Biotechnology. 32 (5): 490–5. doi:10.1038/nbt.2886. PMC 4356947. PMID 24752081.
  80. ^ Jeong S, Park J, Pathania D, Castro CM, Weissleder R, Lee H (February 2016). "Integrated Magneto-Electrochemical Sensor for Exosome Analysis". ACS Nano. 10 (2): 1802–9. doi:10.1021/acsnano.5b07584. PMC 4802494. PMID 26808216.
  81. ^ Shao H, Chung J, Lee K, Balaj L, Min C, Carter BS, et al. (May 2015). "Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma". Nature Communications. 6: 6999. Bibcode:2015NatCo...6.6999S. doi:10.1038/ncomms7999. PMC 4430127. PMID 25959588.
  82. ^ a b van der Pol E, van Gemert MJ, Sturk A, Nieuwland R, van Leeuwen TG (May 2012). "Single vs. swarm detection of microparticles and exosomes by flow cytometry". Journal of Thrombosis and Haemostasis. 10 (5): 919–30. doi:10.1111/j.1538-7836.2012.04683.x. PMID 22394434. S2CID 13818611.
  83. ^ Yuana Y, Oosterkamp TH, Bahatyrova S, Ashcroft B, Garcia Rodriguez P, Bertina RM, et al. (February 2010). "Atomic force microscopy: a novel approach to the detection of nanosized blood microparticles". Journal of Thrombosis and Haemostasis. 8 (2): 315–23. doi:10.1111/j.1538-7836.2009.03654.x. PMID 19840362. S2CID 5963526.
  84. ^ Dragovic RA, Gardiner C, Brooks AS, Tannetta DS, Ferguson DJ, Hole P, et al. (December 2011). "Sizing and phenotyping of cellular vesicles using Nanoparticle Tracking Analysis". Nanomedicine. 7 (6): 780–8. doi:10.1016/j.nano.2011.04.003. PMC 3280380. PMID 21601655.
  85. ^ Tatischeff I, Larquet E, Falcón-Pérez JM, Turpin PY, Kruglik SG (2012). "Fast characterisation of cell-derived extracellular vesicles by nanoparticles tracking analysis, cryo-electron microscopy, and Raman tweezers microspectroscopy". Journal of Extracellular Vesicles. 1: 19179. doi:10.3402/jev.v1i0.19179. PMC 3760651. PMID 24009887.
  86. ^ Pathan M, Keerthikumar S, Ang CS, Gangoda L, Quek CY, Williamson NA, et al. (August 2015). "FunRich: An open access standalone functional enrichment and interaction network analysis tool". Proteomics. 15 (15): 2597–601. doi:10.1002/pmic.201400515. PMID 25921073. S2CID 28583044.
  87. ^ Gaur P, Chaturvedi A (2016). "Mining SNPs in extracellular vesicular transcriptome of Trypanosoma cruzi: a step closer to early diagnosis of neglected Chagas disease". PeerJ. 4: e2693. doi:10.7717/peerj.2693. PMC 5126619. PMID 27904804.
  88. ^ Sjöqvist S, Ishikawa T, Shimura D, Kasai Y, Imafuku A, Bou-Ghannam S, et al. (20 January 2019). "Exosomes derived from clinical-grade oral mucosal epithelial cell sheets promote wound healing". Journal of Extracellular Vesicles. 8 (1): 1565264. doi:10.1080/20013078.2019.1565264. PMC 6346716. PMID 30719240.
  89. ^ a b c Shao X, Zhang M, Chen Y, Sun S, Yang S, Li Q (June 2023). "Exosome-mediated delivery of superoxide dismutase for anti-aging studies in Caenorhabditis elegans". International Journal of Pharmaceutics. 641: 123090. doi:10.1016/j.ijpharm.2023.123090. PMID 37268030. S2CID 259039593.
  90. ^ Santos P, Almeida F (2021-07-14). "Exosome-Based Vaccines: History, Current State, and Clinical Trials". Frontiers in Immunology. 12. doi:10.3389/fimmu.2021.711565. ISSN 1664-3224. PMC 8317489. PMID 34335627.
  91. ^ Gebeyehu A, Kommineni N, Jr DG, Singh MS (2021). "Role of Exosomes for Delivery of Chemotherapeutic Drugs". Critical Reviews in Therapeutic Drug Carrier Systems. 38 (5): 53–97. doi:10.1615/CritRevTherDrugCarrierSyst.2021036301. ISSN 0743-4863. PMC 8691065. PMID 34375513.
  92. ^ Santos P, Almeida F (2021-07-14). "Exosome-Based Vaccines: History, Current State, and Clinical Trials". Frontiers in Immunology. 12. doi:10.3389/fimmu.2021.711565. ISSN 1664-3224. PMC 8317489. PMID 34335627.
  93. ^ "Public Safety Notification on Exosome Products". Center for Biologics Evaluation and Research. U.S. Food and Drug Administration. 20 December 2019.
  94. ^ Knoepfler P (2020-04-23). "Kimera Labs FDA letter cites exosomes for COVID-19, more issues". The Niche. Retrieved 2021-03-02.
  95. ^ "Limited Reporting of Adverse Events Tied to Regenerative Treatments Leaves Consumers Vulnerable". pew.org. 31 July 2020. Retrieved 2021-03-02.
  96. ^ "FDA Warning Letters Week of 4/20/2020: PMA, IDE, & Untitled Letter to Stem Cell Firm". Redica. 2020-04-27. Retrieved 2021-03-02.
  97. ^ "Beyond stem cells, regenerative medicine finds exosomes". Mayo Clinic News Network.
  98. ^ Lee KW, Chan LK, Hung LC, Phoebe LK, Park Y, Yi KH (January 2024). "Clinical Applications of Exosomes: A Critical Review". International Journal of Molecular Sciences. 25 (14): 7794. doi:10.3390/ijms25147794. ISSN 1422-0067. PMC 11277529. PMID 39063033.
  99. ^ Santos P, Almeida F (2021-07-14). "Exosome-Based Vaccines: History, Current State, and Clinical Trials". Frontiers in Immunology. 12. doi:10.3389/fimmu.2021.711565. ISSN 1664-3224. PMC 8317489. PMID 34335627.
  100. ^ Mathivanan S, Simpson RJ (November 2009). "ExoCarta: A compendium of exosomal proteins and RNA". Proteomics. 9 (21): 4997–5000. doi:10.1002/pmic.200900351. PMID 19810033. S2CID 22275212.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Exosome_(vesicle)&oldid=1254828543"